Molecular Diagnostics in Hematology: A Practical Guide for Trainees

The landscape of hematology has transformed dramatically over the past two decades. What was once a field driven primarily by morphology and immunophenotyping has evolved into a precision medicine specialty where molecular diagnostics guide diagnosis, risk stratification, measurable residual disease (MRD) assessment, and treatment selection.

For hematology-oncology trainees, fluency in molecular diagnostics is no longer optional—it is foundational to modern practice.

The integration of next-generation sequencing (NGS), fluorescence in situ hybridization (FISH), conventional cytogenetics, PCR-based assays, and flow cytometry allows us to define hematologic malignancies at the genomic level. This guide focuses on how to select appropriate tests, interpret results, and translate findings into clinical decisions.

The Molecular Diagnostics Toolkit

These technologies are complementary. Knowing when to deploy each modality is essential.

Next-Generation Sequencing (NGS)

NGS panels are now standard for myeloid and many lymphoid malignancies. Most academic centers use targeted panels covering 40–80 clinically relevant genes.

Strengths

• Detects point mutations, small insertions/deletions

• Typical sensitivity ≈5% variant allele frequency (VAF)

• Identifies co-occurring mutations that refine prognosis

• Detects actionable mutations (e.g., FLT3, IDH1/2)

Limitations

• Standard panels may miss balanced translocations

• Turnaround time typically 7–14 days

• VUS interpretation can be challenging

• Does not replace cytogenetics

NGS-based MRD is emerging but not yet standardized across all targets. For certain mutations (e.g., NPM1), PCR-based MRD remains preferred.

Conventional Cytogenetics (Karyotype)

Still essential.

• Detects complex karyotype and unexpected abnormalities

• Required for ELN risk classification in AML

• Turnaround typically 3–5 days

Karyotype remains indispensable and cannot be replaced by targeted NGS alone.

FISH

FISH detects predefined structural abnormalities rapidly (24–48 hours).

Examples

• AML: t(15;17), t(8;21), inv(16)

• CLL: del(17p), del(11q), trisomy 12, del(13q)

• High-grade B-cell lymphoma: MYC, BCL2, BCL6 rearrangements

Limitations: detects only targeted abnormalities; does not detect point mutations.

Flow Cytometry

Provides same-day immunophenotyping and is critical in acute presentations.

Modern multiparameter flow:

• Detects leukemia-associated immunophenotypes (LAIPs)

• MRD sensitivity ≈0.01–0.1%

• Rapid and quantitative

Flow is often the fastest way to assess early treatment response in AML and ALL.

AML: Molecular Diagnostics in Clinical Practice

AML best illustrates how molecular diagnostics directly change management.

Diagnostic Workup for Newly Diagnosed AML

A complete workup should include:

• Flow cytometry

• Conventional cytogenetics

• Disease-directed FISH (especially when urgent)

• NGS myeloid panel

Treatment initiation should not be delayed while awaiting NGS results.

Key AML Molecular Markers That Influence Management

FLT3 Mutations

• Present in ≈30% of AML

• FLT3-ITD with high allelic ratio (>0.5) confers adverse prognosis

• Midostaurin is added to induction and consolidation in FLT3-mutated AML

• Gilteritinib is standard in relapsed/refractory FLT3-mutated AML

Maintenance strategies are evolving, but gilteritinib is not universally considered standard frontline maintenance.

IDH1 and IDH2 Mutations

• Present in ≈15–20% of AML

• Targetable with ivosidenib (IDH1) and enasidenib (IDH2)

• Used in relapsed/refractory disease and in selected newly diagnosed unfit patients

NPM1 Mutations

• Found in ≈30% of AML

• Favorable risk when FLT3-ITD high allelic ratio and adverse cytogenetics are absent

• Excellent MRD marker

Important: NPM1 MRD is monitored using quantitative PCR (qPCR or digital PCR) of mutant transcripts. This remains the preferred approach rather than NGS-based MRD.

TP53 Mutations

• Associated with complex cytogenetics and poor prognosis

• Biallelic (multihit) TP53 confers particularly adverse risk

• Outcomes remain poor with conventional chemotherapy

• Clinical trials should be prioritized when available

MDS: Molecular Profiling Refines Risk

Molecular testing now plays a central role in MDS risk assessment.

The IPSS-M incorporates mutations in 31 genes alongside traditional variables and improves prognostic precision beyond IPSS-R.

High-Impact Mutations

• Multihit TP53: Very poor prognosis

• SF3B1: Associated with ring sideroblasts and relatively favorable prognosis

• Co-mutations (RUNX1, ASXL1, TP53) may override favorable mutations

Distinguishing clonal hematopoiesis (CHIP) from true MDS remains critical, especially in older patients with low-VAF DNMT3A, TET2, or ASXL1 mutations.

Lymphoma and CLL

Aggressive B-Cell Lymphomas

• Double-hit and triple-hit lymphomas (MYC + BCL2 and/or BCL6 rearrangements) require intensive therapy

• FISH is essential for detecting these rearrangements

CLL

• Del(17p) and/or TP53 mutation predicts poor response to chemoimmunotherapy

• First-line therapy should favor BTK inhibitors or venetoclax-based regimens

• IGHV status remains prognostic but is less determinative for therapy choice in the targeted therapy era

Interpreting Molecular Results

Interpretation requires understanding:

• Variant allele frequency (VAF)

• Clonal hierarchy

• Co-occurring mutations

• Clinical context

High VAF mutations may represent dominant clones; low VAF mutations may reflect subclones or CHIP.

Molecular findings must always be integrated with morphology, cytogenetics, and clinical presentation.

When to Order What: A Practical Framework

Urgent Situations

• Flow cytometry

• FISH for critical translocations

• PCR for suspected APL (PML-RARA) or CML (BCR-ABL1)

Comprehensive Workup

• Karyotype

• NGS panel

• Disease-specific FISH

MRD Monitoring

• Flow cytometry (rapid assessment)

• PCR-based MRD (e.g., NPM1, PML-RARA, BCR-ABL1)

• Mutation-directed approaches when validated

Common Pitfalls

• Do not delay induction while awaiting NGS

• Do not overcall CHIP as MDS

• Repeat molecular testing at relapse due to clonal evolution

• Ensure adequate blast percentage for NGS reliability

• Understand your lab’s reporting thresholds

The Future

• Expanded use of NGS-MRD

• Whole-genome sequencing in clinical practice

• Single-cell sequencing

• Cell-free DNA monitoring

• AI-driven prognostic modeling

Key Takeaways

• Molecular diagnostics are essential in modern hematology

• NGS provides comprehensive mutational profiling but does not replace cytogenetics

• FISH and flow cytometry remain critical for rapid decision-making

• FLT3, IDH1/2, NPM1, TP53 directly influence AML management

• PCR-based MRD remains standard for certain targets (e.g., NPM1)

• Always interpret results in clinical context

Conclusion

Molecular diagnostics have transformed hematologic malignancies from morphologically defined diseases into genomically characterized entities with increasingly personalized treatment strategies.

For trainees, mastery lies not in memorizing every mutation, but in understanding:

• Which test to order

• How to interpret VAF and co-mutations

• How molecular results change management

Precision hematology is now the standard of care—and competency in molecular diagnostics is central to delivering high-quality, evidence-based treatment.